Precision Biosciences Inc (DTIL) · Nov 5, 2026 · Other events

Precision BioSciences HBV data deepen cure signal, but remain early

Above the bar — 10/11 HBeAg-negative patients with pgRNA loss; first HBeAg-positive patient became undetectable

Precision BioSciences’ clinical data strengthen the PBGENE-HBV cure story with durable pgRNA loss, including its first HBeAg-positive patient.

Precision is a clinical-stage gene-editing company advancing two lead programs: PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy. PBGENE-HBV was already the company’s main clinical proof point after May 2026 data showed biopsy evidence of cccDNA reduction and durable pgRNA loss, so this filing is an expansion of an existing story rather than a surprise from nowhere.

The HBV efficacy signal is becoming broader and more durable. Of 11 HBeAg-negative patients with detectable pgRNA at baseline, 10 now have undetectable pgRNA, with average durability of five months; the first six patients with pgRNA loss have passed six months. The filing states that “10 currently have undetectable pgRNA after PBGENE-HBV treatment.” 〔0〕

Measure (filing section)CurrentComparison
HBeAg-negative patients with baseline detectable pgRNA (Results)10/115-month average durability
Patients with pgRNA loss past milestone (Results)6>6 months
First HBeAg-positive patient pgRNA (Results)undetectable5,750 copies/mL baseline
cccDNA-derived transcripts (Results)1-log reduction2 administrations at 0.4 mg/kg

The most important incremental news is the HBeAg-positive result. This population carries higher cccDNA and pgRNA burdens, so undetectable pgRNA after treatment suggests the mechanism may not be confined to patients with relatively lower viral reservoirs. The filing says, “In the first HBeAg-positive patient, treated at 0.4 mg/kg, pgRNA decreased from 5,750 copies/mL at baseline to undetectable.”

This is ahead of the early clinical bar, but not yet a clinical cure demonstration. The data reinforce the biological mechanism—cccDNA-derived transcripts fell 10-fold in one patient and pgRNA remained undetectable in most evaluable patients—but the sample remains small, follow-up is incomplete, and the filing does not provide a detailed dose-limiting-toxicity or full safety breakdown. The prior direction was already known from the May EASL update, which reported pgRNA loss in all six evaluable patients, making today’s release more about breadth and durability than a wholly new thesis.

Bottom line: PBGENE-HBV is strengthening its proof-of-mechanism story and has now reached a more demanding HBV subgroup. That is a modest step forward for the program, but the evidence is still early and too small to rewrite the overall company story.

What to watch next

AASLD oral presentation, November 8, 2026

Original filing on SEC EDGAR

More Precision Biosciences Inc news

Precision BioSciences HBV data deepen cure signal, but remain early | DTIL Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.